COVID-19 legislation and relief programs
Find information about the laws, relief programs, and regulations enacted to assist veterinary small business owners, veterinarians, and veterinary…
COVID-19: New paid leave requirements
Learn about paid leave requirements manded under COVID-19 legislation.
NAVTA's Veterinary Nurse Initiative a work in progress
Although the Veterinary Nurse Initiative has seen little state legislative progress, it has made strides in other areas.
FDA given more authority over recalls, records, imports
posted February 1, 2011 A law passed in early January gives federal regulators more authority over food production, including the ability to force…
AVMA request: Commenting deadline for compounding
COVID-19 and student loans: What we know now
The federal government is providing student loan relief during the COVID-19 emergency. We've summarized important information that veterinary student…
Renewed focus on race-day medications
Ssome in the industry are calling for an outright ban on race-day medication, and so is newly introduced federal legislation.
COVID-19 small business loans
Learn about new loan programs provided through the Small Business Administration (SBA) for small businesses coping with the financial impacts of…
COVID-19: Paid leave exemptions for small business
Navigate COVID-19 paid leave requirements and what they mean for your veterinary practice.
Once more around the track
Racetrack-led coalition created to address horse racing deaths, safety concerns
FDA describes legal limits of drug compounding
Agency says few uses allowed for raw active ingredients
Supreme Court hears arguments on downed swine
Meat industry and state government representatives argued before Supreme Court justices whether a California state law can
Judge allows bulk ingredients for compounding
The Food and Drug Administration doesn't have the authority to stop a Florida pharmacy from using bulk pharmaceutical ingredients to
Congress could intervene over modified salmon
Members of Congress are pushing the Food and Drug Administration in opposite directions over whether the agency should finish investigating